Eupraxia Pharmaceuticals Files July 2024 Report
Ticker: EPRX · Form: 6-K · Filed: Jul 3, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing-update, press-release, foreign-issuer
TL;DR
Eupraxia Pharmaceuticals dropped a July 6-K with a press release on 7/3.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on July 3, 2024, reporting on its activities for the month of July. The filing includes a press release dated July 3, 2024, as Exhibit 99.1. Eupraxia Pharmaceuticals Inc. is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' ongoing activities and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as an update and includes a press release, without disclosing significant new financial or operational events.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- July 3, 2024 (date) — Filing and Press Release Date
- Bruce Cousins (person) — Signatory for Eupraxia Pharmaceuticals Inc.
- 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4 (location) — Registrant's principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public pursuant to the laws of their home country, or that they have filed or are required to file with a stock exchange on which their securities are traded.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated July 3, 2024, is included as part of this report.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices of Eupraxia Pharmaceuticals Inc. are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the SEC file number for Eupraxia Pharmaceuticals Inc.?
The SEC file number for Eupraxia Pharmaceuticals Inc. is 001-41923.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc. on July 3, 2024.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2024-07-03 17:01:03
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 16KB
- logo.jpg (GRAPHIC) — 23KB
- image_001.jpg (GRAPHIC) — 114KB
- 0001279569-24-000844.txt ( ) — 218KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: July 3, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer